Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure

Neumora Therapeutics, Inc.

Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.
Company has 180 calendar days, until November 10, 2025, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by Nov 10, 2025, Neumora may seek transfer to Nasdaq Capital Market and additional cure period.
Board approved a reverse stock split (1-for-5 to 1-for-30) subject to stockholder vote at Annual Meeting on May 28, 2025.
Neumora intends to monitor bid price and consider options including the reverse split to maintain listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.